Brookstone Capital Management Sells 4,853 Shares of CVS Health Co. (NYSE:CVS)

Brookstone Capital Management lowered its stake in shares of CVS Health Co. (NYSE:CVSGet Rating) by 11.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,890 shares of the pharmacy operator’s stock after selling 4,853 shares during the quarter. Brookstone Capital Management’s holdings in CVS Health were worth $3,749,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in CVS. CHICAGO TRUST Co NA boosted its stake in CVS Health by 7.1% during the first quarter. CHICAGO TRUST Co NA now owns 46,352 shares of the pharmacy operator’s stock worth $4,691,000 after buying an additional 3,091 shares in the last quarter. Stuart Chaussee & Associates Inc. boosted its stake in CVS Health by 123.0% during the first quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 171 shares in the last quarter. Carnegie Capital Asset Management LLC boosted its stake in CVS Health by 8.5% during the first quarter. Carnegie Capital Asset Management LLC now owns 40,883 shares of the pharmacy operator’s stock worth $4,138,000 after buying an additional 3,196 shares in the last quarter. Veriti Management LLC boosted its stake in CVS Health by 10.1% during the first quarter. Veriti Management LLC now owns 28,770 shares of the pharmacy operator’s stock worth $2,912,000 after buying an additional 2,647 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its stake in CVS Health by 1.2% during the first quarter. Maryland State Retirement & Pension System now owns 101,893 shares of the pharmacy operator’s stock worth $10,313,000 after buying an additional 1,203 shares in the last quarter. 78.00% of the stock is currently owned by institutional investors and hedge funds.

In other CVS Health news, EVP Prem S. Shah sold 16,954 shares of the company’s stock in a transaction that occurred on Friday, April 8th. The stock was sold at an average price of $105.00, for a total transaction of $1,780,170.00. Following the completion of the transaction, the executive vice president now owns 43,453 shares of the company’s stock, valued at approximately $4,562,565. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Daniel P. Finke sold 55,359 shares of the company’s stock in a transaction that occurred on Monday, April 4th. The stock was sold at an average price of $100.13, for a total value of $5,543,096.67. Following the transaction, the executive vice president now directly owns 3,098 shares of the company’s stock, valued at approximately $310,202.74. The disclosure for this sale can be found here. Insiders sold a total of 77,659 shares of company stock valued at $7,882,993 over the last quarter. 0.69% of the stock is owned by insiders.

Shares of CVS stock opened at $91.29 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.88 and a quick ratio of 0.62. The stock has a market cap of $119.71 billion, a PE ratio of 15.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.78. The stock has a 50-day moving average of $97.08 and a 200-day moving average of $101.42. CVS Health Co. has a one year low of $79.33 and a one year high of $111.25.

CVS Health (NYSE:CVSGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The pharmacy operator reported $2.22 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.08. CVS Health had a return on equity of 15.33% and a net margin of 2.67%. The company had revenue of $76.83 billion during the quarter, compared to analysts’ expectations of $75.30 billion. During the same period in the prior year, the business posted $2.04 EPS. CVS Health’s revenue was up 11.2% on a year-over-year basis. As a group, research analysts anticipate that CVS Health Co. will post 8.34 earnings per share for the current year.

A number of research firms have weighed in on CVS. StockNews.com began coverage on shares of CVS Health in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Tigress Financial boosted their target price on shares of CVS Health from $122.00 to $125.00 in a research note on Thursday, April 7th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of CVS Health from $110.00 to $113.00 in a research note on Thursday, May 5th. Sanford C. Bernstein downgraded shares of CVS Health from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $122.00 to $112.00 in a research note on Thursday, May 26th. Finally, Loop Capital assumed coverage on shares of CVS Health in a research note on Thursday, June 16th. They issued a “buy” rating and a $120.00 target price on the stock. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $116.05.

CVS Health Company Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

See Also

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSGet Rating).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Want More Great Investing Ideas?

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.